Gilead Sciences, Inc.
650 Cliffside Drive
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
John C. Martin, PhD, Chairman and Chief Executive Officer
John F. Milligan, PhD, President and Chief Operating Officer
Norbert W. Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer
Kevin Young, Executive Vice President, Commercial Operations
Kristen Metza, Senior Vice President, Human Resources
Susan Hubbard, Vice President, Investor Relations
Amy Flood, Senior Director, Public Affairs
5 articles with Gilead Sciences, Inc.
Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
Kite, a Gilead Company, announced results from the completed Phase 1 of the ZUMA-3 study evaluating KTE-X19, an investigational CD19 chimeric antigen receptor T cell therapy.
Kite, a Gilead Company (Nasdaq: GILD), announced that new data from its cell therapy programs will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago from May 31 – June 4, 2019.
Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis
Gilead Sciences Inc. and insitro announced that the companies have entered into a strategic collaboration to discover and develop therapies for patients with nonalcoholic steatohepatitis.
Funding will Expand Testing, Harm Reduction Services and Healthcare Infrastructure in States with Highest Infection Rates
Gilead to Present New Data From Multiple Liver Disease Research and Development Programs at The International Liver Congress™ 2019
More Than 35 Abstracts Across NASH, PSC and Viral Hepatitis Reflect Ongoing Commitment to Advancing Liver Disease Research and Patient Care